Neurocrine Biosciences | Le Bénéfice D'Exploitation



Operating Profit Changement Date
AbbVie USD 5.72B 1.98B 2025-06
Acadia Pharmaceuticals USD 32.37M 13.08M 2025-06
Agios Pharmaceuticals USD -127056000 20.43M 2025-06
ALKERMES USD 92.98M 79.19M 2025-06
Alnylam Pharmaceuticals USD -16199000 34.28M 2025-06
Amgen USD 2.66B 1.37B 2025-06
Biogen USD 851.8M 540.6M 2025-06
BioMarin Pharmaceutical USD 276.89M 52.99M 2025-06
Cytokinetics USD -111506000 44.12M 2025-06
Dynavax Technologies USD 10.86M 34.49M 2025-06
Exelixis USD 215.68M 28.82M 2025-07
Gilead Sciences USD 2.7B 467M 2025-06
Halozyme Therapeutics USD 202.44M 60.91M 2025-06
Incyte USD 310.82M 105.66M 2025-06
Ionis Pharmaceuticals USD 139.84M 285.84M 2025-06
Neurocrine Biosciences USD 145.6M 121.9M 2025-06
Pfizer USD 2.6B 1.06B 2025-06
Prothena USD -64897000 1.62M 2024-12
Regeneron Pharmaceuticals USD 1.08B 487.8M 2025-06
Repligen USD 5.96M 621K 2025-06
Sarepta Therapeutics USD 115.58M 415.96M 2025-06
Teva Pharmaceutical Industries USD 899M 380M 2025-06
Ultragenyx Pharmaceutical USD -193567000 50.63M 2025-06
Vertex Pharmaceuticals USD 1.15B 123.1M 2025-06


Neurocrine Biosciences Le Bénéfice D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.